Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same

a technology of active drugs and pharmaceutical compositions, applied in the field of contraceptive kits, pharmaceutical compositions and methods, can solve the problems of poor general tolerance and low contraceptive reliability, and achieve the effect of inhibiting ovulation and inhibiting ovulation

Inactive Publication Date: 2019-09-05
LAB LEON FARMA
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012]In one embodiment, the pharmaceutical composition of the present invention may comprise an active contraceptive drug, wherein the pharmaceutical composition allows for a 28 day daily dosing regimen, and wherein after initial administration of the active contraceptive drug has established its contraceptive effect in a patient, the patient may skip up to 4 doses within any 28 day daily dosing regimen period. In a specific embodiment, the skipped up to 4 doses may be on non-consecutive days. In another specific embodiment, the skipped up to 4 doses may be on consecutive days. In another embodiment of the present invention, the pharmaceutical composition may further allow during the 28 day daily dosing regimen for the patient to skip up to two non-consecutive days of the active contraceptive drug, provided the active contraceptive drug skipped dose is taken within about 24 hrs after the up to two skipped non-consecutive days. In another embodiment, the active contraceptive drug may inhibit ovulation. In another embodiment, the contraceptive effect may comprise inhibiting ovulation.
[0055]In another embodiment of the present invention, the kits may comprise one or more packaging units wherein each packaging unit comprises up to 28 daily active dosage units comprising a progestogen-only contraceptive (POC) in a pharmaceutical composition, wherein the pharmaceutical composition allows for a 28 day daily dosing regimen, and wherein after initial administration of POC has inhibited ovulation in a patient, the patient may skip up to 4 doses within any 28 day daily dosing regimen period. In another embodiment, the pharmaceutical composition may further allow during the 28 day daily dosing regimen for the patient to skip up to two non-consecutive days of the POC, provided the POC skipped dose is taken within about 24 hrs after the up to two skipped non-consecutive days. In a specific embodiment, the skipped up to 4 doses may be on non-consecutive days. In another specific embodiment, the skipped up to 4 doses may be on consecutive days. In another embodiment, the POC may inhibit ovulation.

Problems solved by technology

Because of their low contraceptive reliability, POCs have to be taken each day at the same time without a pill-free or placebo interval.
High plasma concentrations are not preferred in patients treated with drospirenone because of a correlation between high Cmax and certain undesirable side effects as well as poor general tolerance when hormonal levels fluctuate too much each and every day.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
  • Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
  • Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same

Examples

Experimental program
Comparison scheme
Effect test

example 1

on of Tablets

[0325]a. Preparation of Drospirenone

[0326]Drospirenone was prepared according to a process similar to that described in WO2006 / 061309. In order to obtain DRSP with an appropriate particle size distribution, DRSP was subjected to an additional process of precipitation as mentioned in the present application.

[0327]Five batches of DRSP were prepared by variants of the above-mentioned precipitation process.

[0328]The analysis of the particle size distribution of each batch was performed by laser diffraction method in wet dispersion (Helos sensor, Sympatec with the wet disperser Quixel). The dispersant used was water. The full particle dispersion was ensured by ultrasonication.

[0329]The specific area was determined by the BET method. The results obtained are shown in table 1 below.

TABLE 1particle size distribution parameters and specific areaof DRSP batchesDRSP BatchPR100003080169080204080257080053d50 (μm)22.424.513.112.619.8d90 (μm)37.437.124.823.434.2d10 (μm)5.92.94.45.37.2...

example 2

Dissolution Profiles

a. Comparison of Tablets A-3 mg (DRSP) with Yasminelle® (Comparative)

[0333]The rate of dissolution of drospirenone from the tablets prepared in Example 1 (A-3mg) was determined by the USP XXIII Paddle Method using a USP Dissolution Test Apparatus 2 including 6 covered glass vessels and 6 paddles.

[0334]Tablets were placed in 900 ml water at a temperature of 37° C.±(0.5° C.) and stirred at 50 rpm. The amount of drospirenone released in water was measured over several hours. The mean percentages of DRSP released (which were related to the amount of drospirenone initially present in the each tablet) were calculated and plotted versus time in order to provide the in vitro dissolution profile of DRSP.

[0335]The in vitro dissolution profile of tablets A-3mg (inventive) is shown in FIG. 2 (see curve n° 2).

[0336]FIG. 2 also provides the dissolution profile obtained for Yasminelle®—tablets which comprised micronized DRSP (comparative) (see curve n° 4).

[0337]Surprisingly, th...

example 3

inetic Studies

Part 1: Evaluation of the Pharmacokinetics Parameters for the Composition According to the Invention (Tablet A-3 mg) as Compared to Yasminelle®

Objectives

[0341]The main objective of the present trial was to assess the bioavailability of an oral test preparation containing drospirenone at 3.0 mg (tablets described in Example 1 obtained from batch 080053 (i.e. A-3mg), called hereunder “test product” hereunder) as compared to a market standard (Yasminelle®, Schering AG, called hereunder “reference product”) after oral administration of a single dose of drospirenone at 3.0 mg under fasting conditions in two different periods, 7 days apart. Yasminelle® comprises 3.0 mg DRSP in micronized form and 0.030 mg of ethinylestradiol.

[0342]In order to investigate the relative bioavailability of the products, the 90% confidence intervals for the intra-individual ratios (test vs. reference) for the endpoint(s) (AUC0-tlast and Cmax of drospirenone) were determined.

[0343]The secondary ob...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
d50 particle sizeaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.

Description

[0001]This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Patent Application 61 / 368,396, filed Jul. 28, 2010.FIELD OF THE INVENTION[0002]The present invention relates to the field of contraceptive kits, pharmaceutical compositions and methods of administering and uses for the kits and pharmaceutical compositions.BACKGROUND OF THE INVENTION[0003]Several contraceptives which comprise synthetic progestogens and no oestrogen are commercially available. These contraceptives called “progestogen-only contraceptives” encompass implants, uterine delivery systems and pills.[0004]Progestogen only contraceptives (“POC”) have the advantage of avoiding the combined administration of estrogens as compared to traditional contraceptive combined pills. POCs, however, display several major drawbacks. Because of their low contraceptive reliability, POCs have to be taken each day at the same time without a pill-free or placebo interval.[0005]The bleeding patterns for women who tak...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/20A61K31/585A61K45/06A61K31/567
CPCA61K9/2054A61K31/567A61K45/06A61K31/585A61K9/2009A61K9/2018A61K9/2013A61K2300/00A61K9/2866A61K9/4816A61K47/10A61K47/32A61K47/38A61K9/1688A61K9/2806
Inventor PERRIN, PHILIPPEVELADA, JOSE LUISDROUIN, DOMINIQUE
Owner LAB LEON FARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap